Welcome to the Oncomine Blog
-
Evaluating NGS technologies for in-house comprehensive genomic profiling
In everyday practice, it is common for pathology labs to evaluate >50% cytological specimens acro... -
Development of a Novel Metric to Measure Genomic Instability - 35th European Congress of Pathology Poster
The theme of the 35th European Congress of Pathology (ECP) “Pathology – a bridge between science and... -
Leveraging Rapid NGS to Advance Hemato-Oncology Research
In a recent Association for Molecular Pathology (AMP) workshop, Dr. Cecilia Yeung shared how her lab... -
How to take advantage of the Oncomine Clinical Research Grant Program
What is the Oncomine Clinical Research Grant Program? The Oncomine Clinical Research Grant is a Ther... -
Simplifying MDS Testing with Next-Generation Sequencing (NGS)
Myelodysplastic syndromes (MDS) are a heterogenous group of myeloid clonal disorders that are charac... -
Genomic Profiling from Initial Assessment to Detection of Measurable Residual Disease (MRD): How NGS Can Rapidly Deliver Key Insights for Myeloid Neoplasms
In his recent webinar, Dr. Bevan Tandon makes a compelling case for how next-generation sequencing (... -
Next-Generation Sequencing (NGS) for Clonality Testing
Lymphoproliferative disorders such as acute lymphoblastic leukemia (ALL), lymphomas, and multiple my... -
Using Next-Generation Sequencing (NGS) to Derive Key Insights in MPN Testing
Myeloproliferative neoplasms (MPNs) are a heterogeneous group of disorders that include essential th... -
Measurable Residual Disease (MRD) in Acute Myeloid Leukemia (AML)
AML Overview Acute myeloid leukemia (AML) is a highly heterogenous group of malignancies, driven by ...